Last checked at 18 Feb 2021 15:39
("ValiRx", the "Company" or the "Group")
Director/PDMR Shareholdings
London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces that it has received notifications on 18 February 2021 of the following share purchases by certain Directors and PDMRs of the Company.
Name | Number of shares purchased | Purchase price | Date of purchase | Number of shares held prior to purchase | Number of shares held following purchase | Percentage shareholding of issued share capital following purchase |
Kevin Cox (Director)
| 22,000 | 22.25p
| 17/02/2021 | 250,333 | 272,333 | 0.42% |
Gerry Desler (Director)
| 22,000 | 22.75p
| 18/02/2021 | 81,668 | 103,668 | 0.16% |
Martin Lampshire (Director)
| 44,000 | 22.70p | 18/02/2021 | - | 44,000 | 0.07% |
Mark Treharne (PDMR)
| 6,095 | 22.78p | 17/02/2021 | - | 6,095 | 0.01% |
Exercise of Warrants
Furthermore, the Company received notifications on 18 February 2021 for the exercise of warrants over 166,666 new ordinary shares in the Company at an exercise price of 13p each ("New Ordinary Shares") by Suzanne Dilly and Kevin Alexander, both Directors of the Company. Details of the exercise are set out in the table below.
Name | Number of warrants exercised | Purchase price | Number of shares held prior to purchase | Number of shares held following exercise | Percentage shareholding of issued share capital following exercise |
Suzanne Dilly
| 83,333 | 13.00p | 233,335 | 316,668 | 0.49%
|
Kevin Alexander
| 83,333 | 13.00p | 167,500 | 250,833 | 0.39% |
Total Voting Rights
The Company had previously applied to list these 166,666 ordinary shares as part of the block listing of 9,034,732 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") which was announced on 19 August 2020. They were admitted to trading on AIM on 24 August 2020.
The total voting rights of the Company comprise 65,049,156 Ordinary Shares which may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
Ends
For further information please contact:
ValiRx plc | Tel: +44 (0) 2476 796496 www.valirx.com |
Suzanne Dilly, CEO | Suzanne.Dilly@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker |
Tel: +44 (0) 20 7469 0930 |
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir |
Tel: +44 (0) 20 8148 3040 valirx@optimumcomms.com |
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||||
a. | Name |
| |||||||||||
2 | Reason for notification |
| |||||||||||
a. | Position/Status | a) Director b) Director c) Director d) PDMR | |||||||||||
b. | Initial notification/ Amendment | Initial notification | |||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||
a. | Name | ValiRx PLC | |||||||||||
b. | LEI |
| |||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares
ISIN: GB00BLH13C52 | |||||||||||
b. | Nature of the transaction | On market Purchase | |||||||||||
c. | Price(s) and volume(s) |
|
|
|
|
| |||||||
| Price(s) | Volume(s) |
| ||||||||||
|
|
| |||||||||||
| |||||||||||||
d. | Aggregated information - Aggregated Volume - Price |
94,095
£0.22610 (weighted average price) | |||||||||||
e. | Date of the transaction |
| |||||||||||
f. | Place of the transaction | London, UK
| |||||||||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||
a. | Name |
| ||||||||
2 | Reason for notification |
| ||||||||
a. | Position/Status | a) Director b) Director | ||||||||
b. | Initial notification/ Amendment | Initial notification | ||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a. | Name | ValiRx PLC | ||||||||
b. | LEI |
| ||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Warrants over new ordinary shares
ISIN: GB00BLH13C52 | ||||||||
b. | Nature of the transaction | Exercise of warrants over new ordinary shares at an exercise price of 13p per share | ||||||||
c. | Price(s) and volume(s) |
|
|
|
|
| ||||
| Price(s) | Volume(s) |
| |||||||
a) £0.13 b) £0.13 | 83,333 83,333 |
| ||||||||
| ||||||||||
d. | Aggregated information - Aggregated Volume - Price |
166,666 £0.13 | ||||||||
e. | Date of the transaction | 18/02/2021 | ||||||||
f. | Place of the transaction | London, UK
| ||||||||